---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-039299"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:32:16.215165+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Soleno reports FY2024 net loss of $175.9M; cash $318.6M; PDUFA for DCCR on March 27, 2025

## Summary
- Net loss $(175.9)M ($4.38/share) vs $(39.0)M in 2023; R&D expense $78.6M, G&A $105.9M.
- Cash, cash equivalents and marketable securities $318.6M at Dec 31, 2024; used $69.1M in operations.
- NDA for DCCR (PWS) under FDA Priority Review with PDUFA target March 27, 2025.
- Entered loan agreement with Oxford for up to $200M ($50M upfront); completed $158.7M public offering in May 2024.
- Appointed Dawn Carter Bir to Board; Matthew Pauls as Lead Independent Director.

## SEC filing metadata
- accession: 0001193125-25-039299
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312525039299/0001193125-25-039299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312525039299/d882131d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-039299
- JSON: https://secwatch.observer/filing/0001193125-25-039299.json
- Plain text: https://secwatch.observer/filing/0001193125-25-039299.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.